Trial Profile
Efficacy of Pomalidomide and Dexamethasone in Patients with Multiple Myeloma and Relapsed and Refractory Light Chain (Al) Amyloidosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Feb 2019
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Amyloid light-chain amyloidosis; Multiple myeloma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 04 Dec 2018 Status changed from recruiting to completed, as reported in an abstract presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 21 Jul 2017 New trial record